Urgent Care Nevada, LLC
Urgent Care Nevada, LLC was paid $34.81M by Medicaid between Jan 2018 and Dec 2024, across 45 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
HENDERSON, NV 89052
Next to other Urgent Care Clinic/Center providers in Nevada
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,436 | $2.83M | |
| 2019 | 95,908 | $5.24M | |
| 2020 | 91,415 | $4.48M | |
| 2021 | 109,740 | $5.91M | |
| 2022 | 131,817 | $6.18M | |
| 2023 | 112,967 | $5.84M | |
| 2024incomplete | 67,190 | $4.34M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 208,174 | 179,746 | $15.55M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 17% | 86,310 | 74,493 | $6.08M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 16% | 58,921 | 51,788 | $5.54M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 69,234 | 61,928 | $4.56M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.6% | 54,143 | 47,833 | $910K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.9% | 11,988 | 10,342 | $661K |
| 87428 | 1.2% | 31,380 | 27,493 | $433K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,956 | 9,856 | $284K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 57,907 | 25,259 | $256K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 44,815 | 39,274 | $157K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 791 | 758 | $84K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,717 | 5,986 | $81K |
33 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,906 | $57K |
| 99205 | Prolong outpt/office vis | <1% | 379 | $48K |
| S9083 | Global fee urgent care centers | <1% | 1,182 | $22K |
| 99201 | <1% | 354 | $15K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 909 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,473 | $13K |
| 81025 | <1% | 2,836 | $9K | |
| 73610 | <1% | 370 | $7K | |
| 73630 | <1% | 400 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 918 | $4K |
| 93000 | <1% | 315 | $3K | |
| 73130 | <1% | 170 | $3K | |
| 81003 | <1% | 2,188 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 914 | $2K |
| 73110 | <1% | 86 | $2K | |
| 69209 | <1% | 195 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,436 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 29 | $805.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 130 | $754.99 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 264 | $657.54 |
| 73140 | <1% | 39 | $597.58 | |
| 73562 | <1% | 19 | $299.00 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 343 | $257.16 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 588 | $185.47 |
| 74018 | <1% | 20 | $104.50 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 101 | $33.35 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 14 | $18.77 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 60 | $12.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $1.01 |
| A9150 | Non-prescription drugs | <1% | 257 | $0.07 |
| 99051 | 0% | 29 | $0.00 | |
| 99000 | 0% | 3,181 | $0.00 | |
| S8110 | Peak expiratory flow rate (physician services) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.